Value of Ki-67 expression in triple-negative breast cancer before and after neoadjuvant chemotherapy with weekly paclitaxel plus carboplatin
Neoadjuvant chemotherapy (NCT) is one of the main treatment strategies for patients with locally advanced breast cancer. In this study, we focused on the predictive and prognostic value of Ki-67 in triple-negative breast cancer (TNBC) patients who received NCT. Data from 280 patients with stage II–I...
Main Authors: | Wang, Ruo-Xi, Chen, Sheng, Jin, Xi, Shao, Zhi-Ming |
---|---|
Format: | Online |
Language: | English |
Published: |
Nature Publishing Group
2016
|
Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4948023/ |
Similar Items
-
Tolerance of weekly metronomic paclitaxel and carboplatin as neoadjuvant chemotherapy in advanced ovarian cancer patients who are unlikely to tolerate 3 weekly paclitaxel and carboplatin
by: Dessai, S. B., et al.
Published: (2016) -
Ki-67 as a Predictor of Response to Neoadjuvant Chemotherapy in Breast Cancer Patients
by: Kim, Kwan Il, et al.
Published: (2014) -
Evaluation of Ki-67 proliferation and apoptotic index before, during and after neoadjuvant chemotherapy for primary breast cancer
by: Burcombe, Russell, et al.
Published: (2006) -
Predictive Significance of p53, Ki-67, and Bcl-2 Expression for Pathologic Complete Response after Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer
by: Kim, Taeryung, et al.
Published: (2015) -
Prognostic and predictive value of Ki-67 in triple-negative breast cancer
by: Wang, Wei, et al.
Published: (2016)